Ophthalmic Consultants: One Vial, Several Bills

Whistleblower Justice Network

In the Ophthalmic Consultants settlement, the Sarasota practice and its physician agreed to pay $4,812,500 to resolve allegations of excessive billing from using single-use eye-drug vials for multiple patients. The government alleged that claims for Lucentis and Eylea reached Medicare, TRICARE and the Federal Employees Health Benefits Program. If you handled the drug inventory, prepared doses or worked on those claims, you may recognize the gap at the center of this case: what came out of the vial and what went onto the bill. The Justice Department announced the settlement on June 30, 2020.

The Drug in the Vial and the Drug on the Claim

The government alleged that Ophthalmic Consultants used a single Lucentis or Eylea vial to provide doses to multiple patients and obtain excessive reimbursement. Both products are single-use medications, even though the vials contain a moderate overfill. The Justice Department identified Lucentis by its generic name, ranibizumab, in describing the eye treatments at issue.

The distinction matters in a practice that buys and bills for drugs. The practice acquires the medication, holds it in inventory, administers it and submits claims for the covered drug and administration services. Medicare’s drug payment system pays by the supported billing units. The amount purchased, the dose administered and the units billed each describe a different part of the transaction.

That is how a vial allegation reaches government money. The alleged problem at Ophthalmic Consultants was that multiple-patient use of single-use vials produced bills for more drug than the practice purchased. We see the absurdity in the alleged result: the medicine stretches across patients, and the government gets the bigger bill.

Overfill also has a specific place in the billing comparison. CMS’s discarded-drug guidance excludes overfill from additional payable single-dose wastage. The dose order, vial size, administration record and waste record need to agree with the drug code’s units. Extra liquid in the container cannot simply become another purchased vial in that account.

What Evidence Does a Whistleblower Need?

For a single-use-vial allegation, useful evidence connects the incoming drug, the doses given, the recorded waste and the quantities billed to government programs. An insider’s knowledge makes those records intelligible: who prepared the doses, how a shared vial was recorded and how the biller arrived at the submitted units. That is the connection we examine when assessing evidence of physician billing fraud.

Purchase invoices show what the practice bought, while delivery and inventory records show the stock available for treatment. No-cost deliveries also help account for the stock, though their billing raises a separate question. Vial and lot records connect the stock to administration records, and the dose and waste entries can then be compared with the claim units. The comparison follows the physical drug all the way to the amount the practice asked the payer to reimburse.

The people doing that work may see different pieces of the same discrepancy. Someone preparing doses may know that several patients received medication from one vial, while someone handling claims may know how each patient’s quantity was entered. We bring those accounts together with the records so that the case explains both the treatment and the billing decision. Your knowledge of how the practice actually worked gives the numbers their meaning.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. We shape your strongest case from what you know about the drug, the claims and the decisions inside the practice.

The Settlement Reached the Inventory Room

The settlement required Ophthalmic Consultants and the physician to enter an integrity agreement with the HHS Office of Inspector General. The Justice Department described routine inventory requirements and requirements addressing proper billing and submission of reimbursement claims. Those controls reached the same connection the allegations put in dispute: the drug on hand and the drug represented to the payer. The agreement ran from June 29, 2020 through June 28, 2023.

The coordinated enforcement effort involved the U.S. Attorney’s Office for the Middle District of Florida, the HHS Office of Inspector General, the Defense Criminal Investigative Service and the Office of Personnel Management Office of Inspector General. The allegations covered claims to all three federal health care programs.

Who Controls the Billing Review?

The 2011 chapter Implementing a Physician Practice Compliance Program, published by Jones and Bartlett, describes how physicians can compromise a review of their own practice. Its discussion says working papers should let an experienced auditor unfamiliar with the review identify the evidence supporting its conclusions. It also describes a practical threat to independence inside a physician practice:

Another organizational impairment might occur if the physicians who are potentially affected by an auditor’s report of findings have an opportunity to review and change the report prior to its issuance.

Implementing a Physician Practice Compliance Program, Jones and Bartlett Publishers, 2011

Applied to a vial review, that means we want to understand both the inventory comparison and how its findings reached the final report. If you saw physicians change a review’s findings about government billing, we want to understand what changed and how it compares with the purchase, administration and claims records.

A Shared Vial Is Its Own Billing Allegation

Progressive Oncology & Hematology’s separate July 2026 settlement announcement described a closely related allegation: single-use vial waste divided among patients, with each billed as receiving a separate vial. The government also alleged billing for chemotherapy obtained free through charitable or grant programs and for drugs prescribed but never administered.

The shared-vial allegation turns on quantities billed across patients, while the free-drug allegation concerns the stock’s source and eligibility for reimbursement. Ophthalmic Consultants puts the shared-vial problem in an eye practice, with purchases, doses and claims at the center of the comparison.

You Know What Came Out of the Vial

If you saw shared vials turn into claims for more drug, speak to one of our Whistleblower Experts about how the vials were billed. We build the case with you, connect your experience to the inventory and claims, and bring in physician billing fraud whistleblower lawyers who understand drug reimbursement. We stay beside you as your knowledge of the practice becomes the foundation of the case.

WHISTLEBLOWER JUSTICE NETWORK CAN HELP YOU
Make a difference.
Whistleblower Justice NetworkReport Fraud
100% CONFIDENTIALFREE CONSULTATION24 / 7 / 365